Moreno, L., Pearson, A. D. J. (2013) How can attrition rates be reduced in cancer drug discovery? Expert Opinion on Drug Discovery, 8 (4). pp. 363-368. ISSN 1746-0441

Full text not available from this repository.

Abstract

Attrition is a major issue in anticancer drug development with up to 95% of drugs tested in Phase I trials not reaching a marketing authorisation making the drug development process enormously costly and inefficient. It is essential that this problem is addressed throughout the whole drug development process to improve efficiency which will ultimately result in increased patient benefit with more profitable drugs. The approach to reduce cancer drug attrition rates must be based on three pillars. The first of these is that there is a need for new pre-clinical models which can act as better predictors of success in clinical trials. Furthermore, clinical trials driven by tumour biology with the incorporation of predictive and pharmacodynamic biomarkers would be beneficial in drug development. Finally, there is a need for increased collaboration to combine the unique strengths between industry, academia and regulators to ensure that the needs of all stakeholders are met.

Item Type:	Editorial
Authors (ICR Faculty only):	Pearson, Andrew
All Authors:	Moreno, L., Pearson, A. D. J.
Additional Information:	ISI Document Delivery No.: 109FT Times Cited: 0 Cited Reference Count: 49 Moreno, Lucas Pearson, Andrew D. J. Informa healthcare London
Uncontrolled Keywords:	anticancer drug development attrition rate biomarkers drug discovery research-and-development hedgehog pathway inhibitor circulating tumor-cells acute myeloid-leukemia clinical-trials breast-cancer targeted agents oncology productivity resistance
Research teams:	Clinical Units > Paediatrics Unit Closed research groups > Paediatric Drug Development & Clinical Trials
Depositing User:	Barry Jenkins
Date Deposited:	11 Apr 2013 09:11
Last Modified:	05 Aug 2015 10:08
URI:	http://publications.icr.ac.uk/id/eprint/12384

Actions (login required)

View Item